| Item Type | Name |
|
Concept
|
Adenine
|
|
Concept
|
Adenine Nucleotides
|
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
|
|
Academic Article
|
Biochemical modulation of cytarabine triphosphate by clofarabine.
|
|
Academic Article
|
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
|
Academic Article
|
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
|
|
Academic Article
|
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
|
|
Academic Article
|
Clofarabine: past, present, and future.
|
|
Academic Article
|
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
|
Academic Article
|
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
|
|
Academic Article
|
Clofarabine and nelarabine: two new purine nucleoside analogs.
|
|
Academic Article
|
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
|
|
Academic Article
|
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
|
|
Academic Article
|
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
|
Academic Article
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
|
Academic Article
|
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
|
|
Academic Article
|
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
|
|
Academic Article
|
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
|
|
Academic Article
|
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
|
|
Academic Article
|
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
|
|
Academic Article
|
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
|
|
Academic Article
|
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
|
|
Academic Article
|
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
|
|
Academic Article
|
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
|
|
Academic Article
|
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
|
|
Academic Article
|
Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
|
|
Academic Article
|
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
|
|
Academic Article
|
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
|
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
|
Academic Article
|
Development and characterization of prototypes for in?vitro and in?vivo mouse models of ibrutinib-resistant CLL.
|